Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefano Cianci has a total of 625 co-authors. Here are the top co-authors by number of shared publications:

  • Salvatore Caruso

    Research Center for the PreDiCTStudy -Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania

    28 shared publications
  • Antonio Cianci

    Department of General Surgery and Medical Surgical Specialties, Gynecological Clinic University of Catania, Via S. Sofia 78, 95124 Catania, Italy

    21 shared publications
  • Giovanni Scambia

    Department of Human Pathology of Adult and Childhood "G. Barresi", Unit of Gynecology and Obstetrics, University of Messina, Messina, Italy

    21 shared publications
  • Salvatore Gueli Alletti

    Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy

    19 shared publications
  • Giuseppe Vizzielli

    Clinic of Obstetrics and Gynecology, “Santa Maria della Misericordia” University Hospital Azienda Sanitaria Universitaria Friuli Centrale Udine Italy

    18 shared publications
  • Salvatore Giovanni Vitale

    Obstetrics and Gynecology Unit, Department of General Surgery and Medical Surgical Specialties, University of Catania, 95124 Catania, Italy

    17 shared publications

Latest Publications

  • Open Access

    Modifiable Lifestyle and Environmental Determinants of Ovarian Cancer Risk: Implications for Primary Prevention

    by Martina Arcieri, Stefano Restaino, Nicoletta Crivellaro, Giorgio Bogani, Sara Pregnolato, Doriana Armenise, Federico Paparcura, Filippo Bordin, Sara Filippin, Lino Del Pup, et al.

    Ovarian cancer (OC) remains the most lethal gynecologic malignancy worldwide, largely due to late-stage diagnosis and the absence of effective screening strategies. As a result, primary prevention is a critical approach to reducing disease burden. This narrative review summarizes current evidence on modifiable lifestyle, reproductive, and environmental factors associated with OC risk, based on a comprehensive PubMed, MEDLINE, Scopus, and Web of Science search conducted through April 2026. Consistent protective associations have been reported for reproductive factors, including parity, breastfeeding, oral contraceptive use, salpingectomy, and tubal ligation. Among lifestyle factors, excess body weight is modestly associated with increased OC risk, while evidence regarding physical activity remains inconclusive. Diets rich in fiber and aligned with a Mediterranean pattern appear protective, potentially through hormonal modulation and anti-inflammatory effects. In contrast, pro-inflammatory diets high in trans fats and refined carbohydrates may increase risk, whereas omega-3 fatty acids show potential protective benefits. Chronic pelvic inflammation, particularly related to Chlamydia trachomatis infection, has been linked to elevated epithelial OC risk. Smoking demonstrates a dose–response association with mucinous tumors. Environmental exposures, including genital talc use and endocrine-disrupting chemicals such as phthalates and bisphenols, have linked to a possible, albeit modest, increase in risk, although the causal mechanisms remain uncertain. Although individual associations are generally modest, their cumulative population impact may be substantial. Integrating lifestyle-based prevention strategies into gynecologic practice and public health initiatives could represent a cost-effective approach to reducing OC incidence and improving women’s health outcomes.


  • Open Access

    Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring

    by Ludovica Pepe, Valeria Zuccalà, Walter Giuseppe Giordano, Giuseppe Giuffrè, Maurizio Martini, Vincenzo Cianci, Cristina Mondello, Massimiliano Berretta, Stefano Cianci, Vincenzo Fiorentino, et al.

    Early diagnosis of ovarian cancer remains one of the most important unmet needs in gynecologic oncology because survival is strongly stage-dependent and most patients still present with disseminated disease. Conventional non-invasive tools, particularly CA-125, transvaginal ultrasound, and composite triage algorithms, remain clinically useful but are limited by suboptimal sensitivity for stage I disease and by reduced specificity in premenopausal women and in benign inflammatory or endometriosis-associated conditions. Circulating tumor DNA (ctDNA) has therefore emerged as a candidate biomarker capable of extending liquid biopsy beyond conventional serology. In ovarian cancer, however, ctDNA implementation is constrained by low tumor shedding in early-stage disease, marked biologic heterogeneity across histotypes, clonal hematopoiesis-related background noise, and major pre-analytical and analytical sources of variability. This narrative review, informed by structured searches of PubMed, Scopus, and Web of Science, examines the evolving evidence for ctDNA mutations, methylation-based assays, multi-omic platforms, and machine-learning models across three distinct clinical contexts: population screening, preoperative triage of adnexal masses, and post-treatment assessment of molecular residual disease. We also discuss positive predictive value, false-positive harms, health-economic implications, standardization initiatives, and ongoing prospective studies. Overall, current evidence suggests that the most plausible near-term role for liquid biopsy in ovarian cancer is not as a universal stand-alone screening test, but as an integrated component of risk stratification and disease-monitoring frameworks that combine molecular signals with clinicopathologic and imaging data.


  • Open Access

    Oral Administration of the Probiotic Lacticaseibacillus rhamnosus CA15 in a Large Cohort of Women with Bacterial Vaginosis and Mixed Vaginitis: Clinical Evidence from a Randomized, Double-Blind, Placebo-Controlled Study

    by Alessandra Pino, Amanda Vaccalluzzo, Stefano Cianci, Marco Palumbo, Giuseppe Caruso, Cinzia Caggia, Cinzia L. Randazzo

    Probiotics represent a valuable approach to boost vaginal health. A randomized double-blind placebo-controlled study was conducted to confirm the health benefits of the orally administered probiotic Lacticaseibacillus rhamnosus CA15 strain in a large cohort of women with bacterial vaginosis and mixed vaginitis, mainly related to mild aerobic vaginitis and vulvovaginal candidiasis. Recruited women were randomly assigned in a 1:1 ratio to receive, for 10 days, oral capsules containing 1 × 1010 colony-forming units of the L. rhamnosus CA15 strain (Active group) or a placebo (Placebo group). Two-hundred women completed this study. Clinical and microbiological parameters were assessed at baseline (T0), 10 days (T1), and 30 days post-treatment (T2). In addition, quality of life was evaluated at T0 and T2. The study protocol was registered on clinicaltrials.gov (ID: NCT05796921). The oral administration of the L. rhamnosus CA15 strain resulted in significant improvements in clinical characteristics of vaginal dysbiosis as well as changes in the vaginal microbiota composition. Furthermore, participants allocated to the Active group reported enhancements in physical and psychological health, social relations, environment, and overall quality of life. No significant changes were observed in the Placebo group. The present study highlights the ability of the L. rhamnosus CA15 to manage vaginal dysbiosis, offering new perspectives for the treatment and prevention of common gynecological disorders.


  • Open Access

    Oral Administration of the Probiotic Lacticaseibacillus rhamnosus CA15 in a Large Cohort of Women with Bacterial Vaginosis and Mixed Vaginitis: Clinical Evidence from a Randomized, Double-Blind, Placebo-Controlled Study

    by Alessandra Pino, Amanda Vaccalluzzo, Stefano Cianci, Marco Palumbo, Giuseppe Caruso, Cinzia Caggia, Cinzia L. Randazzo

    Background/Objectives: Lactobacilli are recognized as indicators of vaginal health and probiotics represent a valuable approach to maintain or restore the homeostasis of the vaginal ecosystem. A randomized double-blind placebo-controlled study was conducted to confirm the health benefits of the orally administered probiotic Lacticaseibacillus rhamnosus CA15 strain, compared to placebo, in a large cohort of women with bacterial vaginosis (BV) and mixed vaginitis (MV), mainly related to mild aerobic vaginitis (AV) and vulvovaginal candidiasis (VVC). Methods: Two-hundred women, exhibiting signs and symptoms of bacterial vaginosis (BV) and mixed vaginitis (MV), were recruited, and randomly assigned in a 1:1 ratio to receive for 10 days, oral capsules containing 1x1010 colony forming units (cfu) of the L. rhamnosus CA15 strain (Active group) or a placebo (Placebo group). Clinical (leucorrhoea, burning, itching, vulvovaginal erythema/oedema, subjective vaginal discomfort, Nugent score, Amsel criteria, and Lactobacillary grade) and microbiological parameters (vaginal microbiota composition) were assessed at baseline (T0), 10 days after the start of the treatment (T1), and 30 days post-treatment (T2). In addition, quality of life was evaluated at baseline and 30 days post-treatment using the WHOQOL-BREF questionnaire. The study protocol was registered on clinicaltrials.gov (ID: NCT05796921). Results: The oral administration of the L. rhamnosus CA15 strain resulted in significant improvements in clinical characteristics of BV (leucorrhea, Nugent score, and Amsel criteria), AV (lactobacillary grade, discharge, and subjective vaginal discomfort), and VVC (leucorrhea, burning, itching, vulvovaginal erythema/oedema, and subjective vaginal discomfort) as well as changes in the vaginal microbiota composition. Furthermore, participants allocated to the Active group reported enhancements in physical and psychological health, social relations, environment, and overall quality of life. No significant changes in clinical and microbiological parameters nor in quality of life, were observed in the Placebo group. Conclusions: The randomized double-blind placebo-controlled study conducted on a large cohort of women highlighted the therapeutic value of the L. rhamnosus CA15 in the management of BV occurring with mixed infections. This probiotic strain represents a safe and effective strategy for restoring the balance of the vaginal microbiota, alleviating clinical symptoms, and enhancing the quality of life of subjects with co-occurring vaginal infections. This finding offers new perspectives for the treatment and prevention of common gynecological disorders.


  • Open Access

    Editorial: Update on the diagnosis and surgical treatment of gynecological tumors

    by S. Cianci, V. A. Capozzi, S. Restaino

    Gynecological tumors, including malignancies of the ovaries, uterus, cervix, vulva, and vagina, account for a substantial proportion of cancer-related morbidity and mortality among women worldwide [1]. Recent progress in diagnostic techniques and surgical interventions has significantly impacted clinical practice, contributing to earlier detection, better risk stratification, and more tailored therapeutic strategies.Advances in imaging technologies, have improved the accuracy of preoperative tumor characterization. These tools facilitate precise staging, of gynecologic malignancies [2].Simultaneously, molecular diagnostics and next-generation sequencing are now integral in the management of ovarian and endometrial cancers. Identification of pathogenic variants such as BRCA1/2, TP53, and mismatch repair (MMR) gene deficiencies allows for more refined classification and targeted treatment planning [3][4][5][6].Emerging diagnostic modalities, such as liquid biopsy, offer non-invasive means for detecting circulating tumor DNA (ctDNA) and other tumor-derived markers, providing a promising approach for monitoring disease recurrence and therapeutic response in real-time [7]. Other promising technologies are actually available as non-coding RNAs (ncRNAs) in gynecologic malignancies, particularly endometrial cancer [8]. While still undergoing validation for widespread clinical use, early studies show considerable potential in gynecologic oncology.Surgical treatment remains the primary modality for most gynecologic cancers. Over the past decade, a paradigm shift toward minimally invasive surgery (MIS) has occurred, with laparoscopic and robotic-assisted techniques increasingly preferred due to their favorable perioperative outcomes.Studies have demonstrated equivalent oncologic safety in selected early-stage endometrial and cervical cancers, along with reduced morbidity and shorter recovery times [9][10][11].Robotic-assisted surgery, in particular, has gained prominence due to its enhanced visualization, dexterity, and ergonomics. While the upfront costs remain a limiting factor, the technology continues to expand, particularly in high-volume centers. For complex cases, such as radical hysterectomy or staging for high-grade endometrial carcinoma, robotics offer technical advantages that may translate into improved functional outcomes, especially when nerve-sparing procedures are employed [12].The management of gynecologic cancers is inherently multidisciplinary. Tumor boards that integrate surgical oncologists, medical oncologists, pathologists, radiologists, and reproductive specialists have become essential in guiding individualized treatment plans. Concurrently, artificial intelligence is beginning to influence diagnostic imaging and risk prediction models, although clinical integration is still in its early stages.The diagnosis and surgical treatment of gynecological tumors continue to evolve, driven by technological innovation, molecular medicine, and a growing emphasis on patient-centered care.


  • Open Access

    Exploring Urinary Tract Injuries in Gynecological Surgery: Current Insights and Future Directions

    by Martina Arcieri, Margherita Cuman, Stefano Restaino, Veronica Tius, Stefano Cianci, Carlo Ronsini, Canio Martinelli, Filippo Bordin, Sara Pregnolato, Violante Di Donato, et al.

    Iatrogenic urinary tract injury is a known complication of pelvic surgery, most commonly occurring during gynecological procedures. The bladder and ureters are particularly vulnerable due to their close anatomical proximity to the uterus. Urinary tract damage can result from various mechanisms, including laceration, ligation, and thermal injury. Incidence rates vary according to the affected organ and surgical type; bladder injuries occur in 0.24% of benign and 0.4–3.7% of oncologic surgeries, whereas ureteral injuries are reported in 0.08% of benign and 0.39–1.1% of oncologic procedures. Timely diagnosis is essential for effective management. When detected intraoperatively, the injury can often be repaired immediately. Surgical treatment options vary depending on the specific nature and location of the bladder or ureteral damage. Delayed diagnosis can significantly impact the patient’s quality of life, increasing the risk of severe complications such as genitourinary fistulas. This narrative review aims to summarize current evidence on the diagnosis, prevention, and treatment of urinary tract injuries occurring during gynecological surgery. It evaluates risk factors, incidence, management, complications, and prevention strategies for iatrogenic bladder and ureteral injuries. Additionally, it highlights the innovative role of artificial intelligence in preventing urologic damage during gynecological procedures. The relevant literature was identified through a structured search of the PubMed database using predefined keywords related to gynecological surgery and urinary tract injury.


  • Open Access

    The Interplay Between Cervicovaginal Microbiota Diversity, Lactobacillus Profiles and Human Papillomavirus in Cervical Cancer: A Systematic Review

    by Giosuè Giordano Incognito, Carlo Ronsini, Vittorio Palmara, Paola Romeo, Giuseppe Vizzielli, Stefano Restaino, Marco La Verde, Orazio De Tommasi, Marco Palumbo, Stefano Cianci

    Background and Objectives: Interest in defining the characteristics of the cervicovaginal microbiota (CVM) in invasive cervical cancer (ICC) is growing, particularly concerning Lactobacillus species, as evidence suggests that these may differ in affected women and potentially interact with Human Papillomavirus (HPV) infection. Understanding these features could have important implications for disease management. Thus, this study aims to systematically review the main characteristics of available literature exploring the relationship between CVM diversity, Lactobacillus profiles, and HPV in ICC; Methods: A comprehensive bibliographic search was conducted across databases, including Medline, Embase, Scopus, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov, in accordance with the to the PRISMA guidelines. The review included studies that met the following inclusion criteria: studies comparing CVM in women with ICC to controls, focusing on Community State Types (CSTs), Lactobacillus profiles, and microbial diversity. Exclusion criteria included commentaries, letters, reviews, and studies without control groups. Variables were analyzed using the Kruskal–Wallis and Fisher’s exact tests, with statistical significance level set at 0.05. Data analysis was conducted and reviewed in a blinded manner. Results: A total of 28 studies published between 2015 and 2024 met the inclusion criteria. A total of 2082 patients were included, with 323 (41.9%) of the 770 cases testing positive for HPV and 327 (24.9%) of the 1312 controls testing positive for HPV. A total of 18 studies specifically examined HPV genotypes. Cervical swabs were employed in 19 out of 28 studies (67.9%), while vaginal swabs were used in 17 studies (60.7%). Additionally, two studies included samples collected via cervical biopsy (7.1%), four studies utilized cervicovaginal lavage (14.3%), and one study used a cervical brush for sample collection (3.6%). Regarding microbiota profiling, 26 studies (92.9%) employed 16S rRNA analysis, while one study (3.6%) utilized whole-genome sequencing (WGS), and another (3.6%) used 16s rDNA. A total of 10 studies (35.7%) examined the distribution of CSTs. Five studies (17.9%) reported on Lactobacillus profiles. Different levels of Lactobacillus crispatus and Lactobacillus iners were observed, along with variations between Lactobacillus-dominant and Lactobacillus-depleted communities. A total of 22 studies (78.6%) assessed α-diversity, and 17 studies (60.7%) examined β-diversity; Conclusions: This study emphasizes the heterogeneous features of the studies exploring the association between alterations in the CVM, HPV, and the development of ICC, suggesting the need for further research to better understand this relationship. These findings could inform new strategies for prevention and treatment.


  • Open Access

    Fertility-Sparing Treatments in Endometrial Cancer: A Comprehensive Review on Efficacy, Oncological Outcomes, and Reproductive Potential

    by Carlo Ronsini, Paola Romeo, Giada Andreoli, Vittorio Palmara, Marco Palumbo, Giuseppe Caruso, Pasquale De Franciscis, Giuseppe Vizzielli, Stefano Restaino, Vito Chiantera, et al.

    Endometrial cancer (EC) affects 3–14% of women under 40 who wish to preserve their fertility. The standard treatment for EC is a hysterectomy with salpingo-oophorectomy. However, for those desiring fertility preservation, oral progestogens such as medroxy-progesterone acetate (MPA) or megestrol acetate (MA) are the most common therapies in Fertility-Sparing Treatment (FST). Other treatments include gonadotropin-releasing hormone agonist (GnRHa), levonorgestrel-releasing intrauterine system (LNG-IUS), and metformin plus progestin. This comprehensive review evaluates the best FST options for women with reproductive potential. PubMed, EMBASE, and Scopus were searched in June 2023 using specific keywords. Studies included in the review focused on patients with EC undergoing FST, with outcomes such as complete response rate (CRR), recurrence rate (RR), pregnancy rate (PR), and live birth rate. Eighteen studies met the inclusion criteria, involving 23,976 patients. In only-oral progestin trials, CRR ranged from 18% to 100%; RR ranged from 0% to 81.8%; Death Rate ranged from 0% to 3.6%. In studies combining oral progestin with LNG-IUS, CRR ranged from 55% to 87.5%; RR ranged from 0% to 41.7%; Death Rate was 0%. Most patients with Stage IA EC received MPA or MA. Fertility-related outcomes were reported in 15 studies. PR ranged from 4 to 44 patients in trials involving only oral progestins. When combining oral progestin with LNG-IUS, PR ranged from 1 to 46 patients. Progestin therapy, including oral MPA and MA, is considered safe and effective, with limited evidence supporting the use of LNG-IUS.


  • The Interplay between Cervicovaginal Microbiota Diversity, Lactobacillus Profiles and Human Papillomavirus in Cervical Cancer: A Systematic Review

    by Giosuè Giordano Incognito, Carlo Ronsini, Vittorio Palmara, Paola Romeo, Giuseppe Vizzielli, Stefano Restaino, Marco La Verde, Orazio De Tommasi, Marco Palumbo, Stefano Cianci

    INPLASY202530027 The Interplay between Cervicovaginal Microbiota Diversity, Lactobacillus Profiles and Human Papillomavirus in Cervical Cancer: A Systematic Review Keywords: cervical cancer; microb…


  • Open Access

    Pelvic Actinomycosis and Diagnostic Complexity: Case Report with Literature Review

    by Stefano Restaino, Benedetta Gomba, Cecilia Zero, Guglielmo Stabile, Carlo Ronsini, Luigi Della Corte, Stefano Cianci, Federica Perelli, Ilaria Piacenti, Lorenza Driul, et al.

    Introduction: Actinomyces are commensal bacteria that colonize various sites in the human body. Under certain predisposing conditions, they can proliferate and cause granulomatous inflammation in different tissues. Pelvic actinomycosis is an extremely rare condition; its significance lies in the fact that it can be easily misdiagnosed as gynecological malignancy based on clinical manifestations and imaging findings. According to the literature, this type of inflammatory disease is a common mimic of ovarian cancer. Objective and methods: This paper aims to provide a comprehensive overview of the characteristics of pelvic actinomycosis through a literature review and the description of two cases collected between 2023 and 2024 at Azienda Ospedaliera Universitaria Santa Maria della Misericordia in Udine Italy.